Riociguat for the Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (CHEST-1)

CHEST Journal ◽  
2012 ◽  
Vol 142 (4) ◽  
pp. 1023A ◽  
Author(s):  
Hossein Ghofrani ◽  
Friedrich Grimminger ◽  
Marius Hoeper ◽  
Nick Kim ◽  
Eckhard Mayer ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Thromboembolic Pulmonary Hypertension

scholarly journals Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

2019 ◽  
Vol 9 (2) ◽  
pp. 204589401984643 ◽  
Author(s):  
Pilar Escribano-Subias ◽  
Hakim Bendjenana ◽  
Paula S. Curtis ◽  
Irene Lang ◽  
Anton Vonk Noordegraaf
Keyword(s):  
Pulmonary Hypertension ◽  
Adverse Event ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
Early Termination ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Thromboembolic Pulmonary Hypertension ◽  
Secondary Endpoints

This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary and some secondary endpoints were observed; adverse event profiles were similar between groups.

scholarly journals Selexipag for the treatment of chronic thromboembolic pulmonary hypertension

2021 ◽  
pp. 2101694
Author(s):  
Takeshi Ogo ◽  
Hiroto Shimokawahara ◽  
Hideyuki Kinoshita ◽  
Seiichiro Sakao ◽  
Kohtaro Abe ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Scale Score ◽  
Large Scale ◽  
Treatment Options ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
Functional Class ◽  
World Health ◽  
Controlled Study ◽  
Double Blind ◽  
Thromboembolic Pulmonary Hypertension

Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remain limited. Selexipag, an oral selective IP prostacyclin-receptor agonist approved for pulmonary arterial hypertension, is a potential treatment option for CTEPH.In this multicentre, randomised, double-blind, placebo-controlled study, 78 Japanese patients with inoperable CTEPH or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy and/or balloon pulmonary angioplasty were randomly assigned to receive placebo or selexipag. The primary endpoint was the change in pulmonary vascular resistance (PVR) from baseline to week 20. The secondary endpoints were changes in other haemodynamic parameters, 6-min walk distance (6 WMD), Borg Dyspnoea Scale score, World Health Organisation (WHO) functional class, EuroQol 5 dimensions 5-level and N-terminal pro-brain natriuretic peptide.The change in PVR was −98.2±111.3 dyn·s·cm−5 and −4.6±163.6 dyn·s·cm−5 in the selexipag and placebo groups, respectively (mean difference, −93.5 dyn·s·cm−5; 95% confidence interval, −156.8, −30.3; p=0.006). The changes in cardiac index (p<0.001) and Borg Dyspnoea Scale score (p=0.036) were also significantly improved over placebo. 6WMD and WHO functional class were not significantly improved. The common adverse events in the selexipag group were corresponded to those generally observed following a prostacyclin analogue is administered.Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity remained unchanged. Further large-scale investigation is necessary to prove the role of selexipag in CTEPH.

High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension

2003 ◽  
Vol 90 (09) ◽  
pp. 372-376 ◽  
Author(s):  
Diana Bonderman ◽  
Peter Turecek ◽  
Johannes Jakowitsch ◽  
Ansgar Weltermann ◽  
Christopher Adlbrecht ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
University Hospital ◽  
Clotting Factor ◽  
Controlled Study ◽  
Elevated Plasma ◽  
High Prevalence ◽  
Thromboembolic Pulmonary Hypertension ◽  
Pulmonary Arterial ◽  
One Year

SummaryChronic thromboembolic pulmonary hypertension (CTEPH) is an enigmatic disorder lacking signs, symptoms and classical risk factors for venous thromboembolism.The objective of the prospective case controlled study, carried out at the Pulmonary Hypertension Unit, University Hospital Vienna, Austria, was to investigate whether plasma FVIII is elevated in CTEPH patients.The study examined 122 consecutive patients diagnosed with CTEPH. Plasma FVIII was measured and compared with plasma FVIII of healthy controls (n=82) and of patients with non-thromboembolic pulmonary arterial hypertension (PAH, n=88).Results show that CTEPH patients had higher FVIII levels than controls (233±83IU/dl versus 123±40IU/dl, p<0.0001) and PAH patients (158±61IU/dl, p<0.0001). Plasma FVIII one year after surgery (212±94IU/dl) was statistically unchanged compared with preoperative values (FVIII: 226±88IU/dl, n=25). FVIII>230IU/dl was more prevalent in CTEPH patients (41%) than in controls (5%, p<0.0001) and PAH patients (22%, p=0.022).We can conclude that elevated plasma FVIII is the first prothrombotic factor identified in a large proportion of CTEPH patients.

A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis

CHEST Journal ◽  
2020 ◽  
Vol 158 (2) ◽  
pp. 637-645 ◽  
Author(s):  
Steven D. Nathan ◽  
Kevin.R. Flaherty ◽  
Marilyn.K. Glassberg ◽  
Ganesh Raghu ◽  
Jeffrey Swigris ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
At Risk ◽  
Pulmonary Hypertension ◽  
Pulmonary Fibrosis ◽  
Inhaled Nitric Oxide ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document